COMPOSITIONS AND METHODS FOR TREATING LUNG INJURY OR ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)

摘要

Disclosed herein are compositions and methods of treating lung injury or ARDS secondary to sepsis or any related inflammatory or immune response, including COVID-19, in a human subject by administering an effective amount of a GM-CSF antagonist, and then assessing the reduction in morbidity and mortality, and the improvement in one or more scales and/or scores commonly used to assess the severity of lung injury or ARDS. Also disclosed are compositions and administration protocols for the use of a GM-CSF antagonist (e.g., a monoclonal anti-GM-CSF antibody (such as gimsilumab or namilumab), or an anti-GM-CSF receptor antibody, or an antigen-binding fragment thereof to treat or prevent pathophysiology associated with COVID-19.